FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...

Govt to raise cap on loan guarantees in a bid to reverse plummeting vehicle sales and surge in non-performing loans ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Q4 2024 Management View CEO Brian Casey highlighted the company’s success in institutional sales, stating that the team won and funded eight mandates totaling over $600 million in 2024, doubling the ...

The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Vertiv is projecting another year of sales growth as the bustling data center market continues to provide it with strong pipeline activity.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, primarily through its Enhaze platform. This technology, based on the rHuPH20 ...

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's non-opioid pain relief drug, Journavx, received FDA approval on Jan. 30. The drug is ...